Navigation Links
Nile Therapeutics Reports 2010 Third Quarter Financial Results
Date:11/12/2010

nes, expected patient enrollment, anticipated benefits of CD-NP, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission on March 3, 2010. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.Condensed Statement of Operations(unaudited)Three months ended September 30,Nine months ended September 30,Period fromAugust 1, 2005 (inception)2010200920102009through September 30, 2010Grant income$
-$
-$
-$
-$
482,235Operating expenses:Research and development1,148,6411,149,2323,517,8223,577,26425,295,877General and administrative664,095869,1431,732,7452,729,30013,729,507Total operating expenses1,812,7362,018,3755,250,5676,306
'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... -- RadiologyAuction will have their first auction starting May 5 ... the end of the auction on May 27 th ... Cr,s, Agfa and Sony, printers and GE portable x-rays ... equipment will be available at later auctions each month ... buying and selling imaging equipment, the brokers at RadiologyAuction ...
(Date:5/4/2015)... -- Makindus, Inc. a specialty pharmaceutical development company focused on ... has granted orphan drug designation for their lead candidate, ... "We are extremely pleased to now have orphan drug ... for Europe . This complements and ... States for which orphan designation has already ...
(Date:5/4/2015)... , May 4, 2015   HeartWare International, Inc ... invasive, miniaturized circulatory support technologies that are revolutionizing the treatment ... Doug Godshall , is scheduled to present at the ... Las Vegas on Thursday, May 14, ... The live webcast of the Company,s presentation at the conference ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2
... As part of the Help America ... the first approved candidate with hearing instruments at no ... came into the Beaverton clinic because of hearing concerns. ... those that have hearing loss and limited financial resources ...
... Spectrum Control, Inc. (Nasdaq: SPEC ), a leading ... today that it will release its fourth quarter and fiscal ... close of the market. Following the release, Spectrum Control will ... discuss the Company,s operating results for the quarter and fiscal ...
Cached Medicine Technology:Accurate Hearing & Audiology Clinics / Help America Hear - One Person at a Time 2
(Date:5/4/2015)... 2015 CCL, a top-ranked, global provider ... program to other leadership development consultancies. “The CCL ... and successful practitioners, expanding our capacity to drive results ... John R. Ryan, CCL President and CEO. , As ... Partner Network , it will schedule a one-on-one conference ...
(Date:5/4/2015)... May 04, 2015 San Diego ... ceremony at their brand new, 13,700 square foot facility ... new building will not only provide fertility treatment and ... also offer community and educational events to a number ... is located next door to their current Carmel Valley/Del ...
(Date:5/4/2015)... Dr. Benjamin Stong of Kalos Facial ... latest non-surgical double-chin eliminator. Dr. Stong is double ... Atlanta to offer Kybella treatments . The FDA ... under the chin, promising to safely dissolve fat deposits ... who sought immediate solutions for their double chin were ...
(Date:5/4/2015)... 04, 2015 Unlike some camps, the Nike Middle ... The goal is to educate first and train second, with ... ensures that the young runners are building the knowledge base needed ... of the topics covered include Effort Based Training, Running Heroes, Running ... to be? This is not a camp where kids come ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Dr. Richard ... has been chosen to receive the America’s Best Dentist ... Dr. Champagne’s selection as a top dentist is a ... to continuing education and his compassion for his patients. ... professionals who exemplify excellence in their field. These nominees ...
Breaking Medicine News(10 mins):Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2
... delivery combination selectively crosses the tight barrier that protects the ... to brain tumors, a research team led by scientists from ... the January issue of the Journal of Clinical Investigation ... the targeted particles guide payloads to image tumors, treat tumors, ...
... (HealthDay News) -- HIV-positive teens and young women are more likely ... who do not have HIV, a new study finds. Researchers ... aged 13 to 24, who had been treated at four hospitals ... some more than once, for a total of 96 pregnancies. ...
... By Serena Gordon HealthDay Reporter , TUESDAY, ... for profit are more likely to have patients who require ... who need longer times in hospice care, research reveals. ... hospices a flat daily rate, regardless of care needs -- ...
... research from University of Michigan says brain scans showing ... the person whose brain is being scanned. Emily ... recently led a study that scanned the brain activity ... would have an impact on their ability to quit ...
... from human placenta left over from live births and ... one kind of melatonin receptor, MT1. This potentially therapeutic ... laboratory test tube and animal models of stroke. ... with melatonin receptor MT2. Researchers from the University ...
... HealthDay Reporter , TUESDAY, Feb. 1 (HealthDay News) ... from meningococcal meningitis, a potentially deadly infection of the ... up-to-date whooping cough vaccines in light of recent outbreaks, ... American Academy of Pediatrics issues updated vaccination guidelines annually. ...
Cached Medicine News:Health News:Targeted particle fools brain's guardian to reach tumors 2Health News:Targeted particle fools brain's guardian to reach tumors 3Health News:Targeted particle fools brain's guardian to reach tumors 4Health News:HIV Linked to Higher Pregnancy Rate in Young Women 2Health News:For-Profit Hospices May Prefer Certain Types of Patients: Study 2Health News:For-Profit Hospices May Prefer Certain Types of Patients: Study 3Health News:Brain scans predict likely success when it comes to quitting smoking 2Health News:Transplanted human placenta-derived stem cells show therapeutic potential in stroke models 2Health News:Pediatricians Issue New Vaccination Recommendations 2Health News:Pediatricians Issue New Vaccination Recommendations 3
4 hour identification of over 70 medically important, oxidase-negative, gram-negative bacilli, including E. coli, based on enzyme technology....
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens....
Medicine Products: